MITOPE

First-in-human dose escalation phase 1 evaluating a novel covalent inhibiter targeting mitochondrial PRX3 completed enrollment in 2023. MITOPE is currently recruiting patients with pleural effusion due to mesothelioma or other disease of the lungs as part of ongoing multi-center phase 2 dose expansion in the UK.

Trials.gov